MMSINasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
MERIT MEDICAL SYSTEMS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$89.96+0.76 (+0.85%)
Close on Oct 19, 2026
- Market cap
- $5.40B
- P/E (TTM)
- 37.2
- Dividend yield
- –
MERIT MEDICAL SYSTEMS INC revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Single reportable segment | $418.84M | $381.88M | – | – | $382.46M | $355.35M | – | – | – | – | – | – | 100.0% | +9.5% |
| Endoscopy | – | – | $20.06M | $17.73M | $18.44M | $16.64M | $17.46M | $16.99M | $10.19M | $10.13M | $9.29M | $9.15M | – | – |
| Cardiovascular | – | – | $373.88M | $366.43M | $364.03M | $338.71M | $337.70M | $322.86M | $327.82M | $313.37M | $315.23M | $306.08M | – | – |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Endoscopy | – | – | $5.62M | $4.83M | $5.64M | $2.50M | -$212.00K | -$294.00K | $3.03M | $3.02M | $2.14M | $2.52M | – |
| Cardiovascular | – | – | $48.57M | $37.78M | $41.24M | $38.54M | $36.78M | $37.56M | $42.91M | $32.91M | $31.47M | $32.62M | – |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Foundational | $280.96M | $255.48M | – | – | $262.38M | $240.38M | – | – | – | – | – | – | 67.1% | +7.1% |
| Access | $161.79M | – | – | – | $152.12M | – | – | – | – | – | – | – | 38.6% | +6.4% |
| Therapeutic | $137.88M | $126.40M | – | – | $120.08M | $114.97M | – | – | – | – | – | – | 32.9% | +14.8% |
| OEM | $48.34M | – | – | – | $43.22M | – | – | – | – | – | – | – | 11.5% | +11.8% |
| Vascular Intervention | $41.65M | – | – | – | $34.96M | – | – | – | – | – | – | – | 9.9% | +19.2% |
| Vascular Intervention | $34.44M | – | – | – | $32.26M | – | – | – | – | – | – | – | 8.2% | +6.8% |
| Cardiac Therapies | $28.51M | – | – | – | $22.93M | – | – | – | – | – | – | – | 6.8% | +24.3% |
| Procedural Solutions | $27.95M | – | – | – | $31.74M | – | – | – | – | – | – | – | 6.7% | -11.9% |
| Oncology | $25.77M | – | – | – | $23.94M | – | – | – | – | – | – | – | 6.2% | +7.6% |
| Endoscopy | $23.65M | – | – | – | $18.40M | – | – | – | – | – | – | – | 5.6% | +28.5% |
| OEM | $12.80M | – | – | – | $9.74M | – | – | – | – | – | – | – | 3.1% | +31.5% |
| Renal Therapies | $12.71M | – | – | – | $12.82M | – | – | – | – | – | – | – | 3.0% | -0.8% |
| Other | $1.24M | – | – | – | $346.00K | – | – | – | – | – | – | – | 0.3% | +257.2% |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $252.05M | $226.52M | $238.22M | $230.60M | $227.08M | $213.56M | $213.53M | $206.49M | $194.66M | $186.09M | $188.54M | $187.51M | 60.2% | +11.0% |
| International | $166.79M | $155.36M | $155.71M | $153.56M | $155.38M | $141.79M | $141.63M | $133.35M | $143.34M | $137.41M | $135.97M | $127.73M | 39.8% | +7.3% |
From the segment and revenue-disaggregation notes of Merit Medical Systems's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.